论文部分内容阅读
目的观察尿激酶联合低分子肝素治疗颅内静脉窦血栓形成(CVST)的临床效果。方法选择广德人民医院2012年1月-2013年12月收治的CVST患者86例,按照治疗方法分为两组,每组43例。观察组采用尿激酶联合低分子肝素治疗,对照组仅采用低分子肝素治疗。比较两组治疗有效率,1个月后脑脊液压力恢复正常率及不良反应发生情况。采用χ2检验对数据进行统计学分析。结果观察组和对照组治疗有效率分别为93.02%和72.09%,差异有统计学意义(P<0.05)。治疗1个月后,观察组和对照组脑脊液压力恢复正常率分别为86.05%和62.79%,差异有统计学意义(P<0.05)。治疗过程中,两组患者均未见任何不良反应。结论尿激酶联合低分子肝素治疗颅内静脉窦血栓形成,安全有效,值得临床推广。
Objective To observe the clinical effect of urokinase combined with low molecular weight heparin in the treatment of intracranial venous sinus thrombosis (CVST). Methods Eighty-six patients with CVST who were admitted to Guangde People’s Hospital from January 2012 to December 2013 were divided into two groups according to the treatment method, 43 cases in each group. The observation group was treated with urokinase combined with low molecular weight heparin and the control group with only low molecular weight heparin. The therapeutic efficacies of both groups were compared, and the normal rate of cerebrospinal fluid pressure regain and the incidence of adverse reactions after 1 month were compared. The χ2 test was used to analyze the data. Results The effective rates of the observation group and the control group were 93.02% and 72.09%, respectively, with statistical significance (P <0.05). After 1 month of treatment, the normal rates of cerebrospinal fluid pressure recovery in the observation group and the control group were 86.05% and 62.79%, respectively, with statistical significance (P <0.05). During treatment, no adverse reactions were seen in both groups. Conclusion Urokinase combined with low molecular weight heparin treatment of intracranial venous sinus thrombosis, safe and effective, worthy of clinical promotion.